AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies

AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies

Financing supports advancement of AHB-137 toward potential commercialization, including its Phase 3 registrational program and commercialization readinessProceeds will also accelerate AHB-171 and next-generation combination approaches designed to advance functional cure for chronic hepatitis BSeries C brings AusperBio's total capital raised…

AusperBio Raises $120M Series C to Advance Hepatitis B Drug AHB-137

Chronic hepatitis B affects more than 250 million people worldwide, yet existing treatments only suppress the virus rather than eliminate it. Patients typica...